Show simple item record

dc.creatorBaudrand, René
dc.creatorPojoga, Luminita H
dc.creatorVaidya, Anand
dc.creatorGarza, Amanda E
dc.creatorVoehringer, Paul A
dc.creatorJeunemaitre, Xavier
dc.creatorHopkins, Paul N
dc.creatorYao, Tham M
dc.creatorWilliams, Jonathan
dc.creatorAdler, Gail K
dc.creatorWilliams, Gordon H
dc.date.accessioned2021-08-23T22:59:58Z
dc.date.available2021-08-23T22:59:58Z
dc.date.issued2015
dc.identifier.urihttp://hdl.handle.net/10533/252745
dc.description.abstractBackground-Statins substantially reduce cardiovascular mortality and appear to have beneficial effects independent of their lipid-lowering properties. We evaluated the hypothesis that statin use may modulate the secretion of aldosterone, a well-known contributor to cardiovascular disease. Methods and Results-We measured adrenal hormones in 2 intervention studies. In study 1 in hypertensive subjects, aldosterone was analyzed at baseline and after angiotensin II stimulation on both high- and low-sodium diets (1122 observations, 15% on statins for >3 months). Statin users had 33% lower aldosterone levels in adjusted models (P<0.001). Cortisol was not modified by statins. In secondary analyses, the lowest aldosterone levels were seen with lipophilic statins and with higher doses. Statin users had lower blood pressure and reduced salt sensitivity of blood pressure (both P<0.001). In study 2, aldosterone was measured in diabetic patients on a high-sodium diet, before and after angiotensin II stimulation (143 observations, 79% statin users). Again, statin users had 26% lower aldosterone levels (P=0.006), particularly those using lipophilic statins. Ex vivo studies in rat adrenal glomerulosa cells confirmed that lipophilic statins acutely inhibited aldosterone, but not corticosterone, in response to different secretagogues. Conclusions-Statin use among hypertensive and diabetic subjects was associated with lower aldosterone secretion in response to angiotensin II and a low-sodium diet in 2 human intervention studies. This effect appeared to be most pronounced with lipophilic statins and higher doses. Future studies to evaluate whether aldosterone inhibition may partially explain the robust cardioprotective effects of statins are warranted.
dc.language.isoeng
dc.relation.urihttps://doi.org/10.1161/CIRCULATIONAHA.115.016759
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.titleStatin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects
dc.typeArticulo
dc.description.conicytinstrumentRegular 2015
dc.identifier.folio1150327
dc.description.conicytprogramFONDECYT
dc.relation.contesthandle/10533/111557
dc.rights.driverinfo:eu-repo/semantics/article
dc.rights.driverinfo:eu-repo/semantics/openAccess
dc.title.journalCIRCULATION
dc.relation.instrumenthandle/10533/111541
dc.relation.programhandle/10533/108045
dc.description.shortconicytprogramFONDECYT
dc.type.openaireinfo:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item

This item appears in the following Collection(s)

Show simple item record